EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry

[1]  S. Pinder,et al.  Breast Pathology: A Volume in the Foundations in Diagnostic Pathology series , 2011 .

[2]  S. Leung,et al.  Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers , 2010, Breast Cancer Research and Treatment.

[3]  S. Bull,et al.  Prognostic Effect of Basal-Like Breast Cancers Is Time Dependent: Evidence from Tissue Microarray Studies on a Lymph Node–Negative Cohort , 2008, Clinical Cancer Research.

[4]  S. Bull,et al.  Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors , 2008, Breast Cancer Research and Treatment.

[5]  J. Bartlett,et al.  Genetic alterations of CCND1 and EMSY in breast cancers , 2008, Histopathology.

[6]  M. Goggins,et al.  Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas. , 2008, International journal of clinical and experimental pathology.

[7]  L. Skoog,et al.  Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer , 2007, Oncogene.

[8]  A. Ashworth,et al.  BRCA1 dysfunction in sporadic basal-like breast cancer , 2007, Oncogene.

[9]  A. Whittemore,et al.  BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays , 2007, The American journal of surgical pathology.

[10]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[11]  Robin L. Jones,et al.  Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis , 2006, Modern Pathology.

[12]  Stephen Chia,et al.  Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. , 2006, Gynecologic oncology.

[13]  Yasodha Natkunam,et al.  TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays , 2005, Modern Pathology.

[14]  K. Jirström,et al.  Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. , 2005, Cancer research.

[15]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[16]  Robert L Sutherland,et al.  Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. , 2005, Endocrine-related cancer.

[17]  A. Papanikolaou,et al.  Cyclin D1 in breast cancer pathogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Peter Schraml,et al.  Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.

[19]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[20]  Luke Hughes-Davies,et al.  Amplification of the BRCA2 Pathway Gene EMSY in Sporadic Breast Cancer Is Related to Negative Outcome , 2004, Clinical Cancer Research.

[21]  Norman Boyd,et al.  The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer , 2004, Breast Cancer Research.

[22]  L. Rydén,et al.  Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients , 2004, British Journal of Cancer.

[23]  G. Peters,et al.  Chromosome 11q13 markers and D-type cyclins in breast cancer , 2004, Breast Cancer Research and Treatment.

[24]  Luke Hughes-Davies,et al.  EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer , 2003, Cell.

[25]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Peter Devilee,et al.  Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .

[27]  Ash A. Alizadeh,et al.  Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. , 2002, The American journal of pathology.

[28]  A. Whittemore,et al.  Comparison of DNA‐ and RNA‐Based Methods for Detection of Truncating BRCA1 Mutations , 2002, Human mutation.

[29]  I. Bièche,et al.  Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays , 2002, British Journal of Cancer.

[30]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[31]  G. Casey,et al.  Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers , 2001, Molecular pathology : MP.

[32]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[33]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Buckle,et al.  Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. , 1998, Genes & development.

[35]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[36]  M. Schwab.  Amplification of oncogenes in human cancer cells , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[37]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[38]  R. Zeillinger,et al.  Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. , 1997, Cancer research.

[39]  M. Ewen,et al.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4 , 1997, Molecular and cellular biology.

[40]  A. Marchetti,et al.  Cyclin‐d1‐gene amplification and expression in breast carcinoma: Relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21waf1 immunohistochemical expression , 1997, International journal of cancer.

[41]  D. Barnes.  Cyclin D1 in mammary carcinoma , 1997, The Journal of pathology.

[42]  R. Bernards,et al.  CDK-Independent Activation of Estrogen Receptor by Cyclin D1 , 1997, Cell.

[43]  M. L. Beau,et al.  Gene mapping by FISH. , 1997, Methods in molecular biology.

[44]  M. Stratton,et al.  Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. , 1997, British Journal of Cancer.

[45]  D. Horsfall,et al.  Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  Sheila Seal,et al.  BRCA2 mutations in primary breast and ovarian cancers , 1996, Nature Genetics.

[47]  E. Schmidt,et al.  Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[48]  F. Collins,et al.  Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  B. Kemper,et al.  Screening for mutations by enzyme mismatch cleavage with T4 endonuclease VII. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Birnbaum,et al.  Patterns of dna amplification at band q13 of chromosome 11 in human breast cancer , 1994, Genes, chromosomes & cancer.

[51]  M. J. van de Vijver,et al.  Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. , 1992, Cancer research.